EMA issues positive opinion, recommends full approval of IMBRUVICA(R) (ibrutinib)
Pharmacyclics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA® (ibrutinib) in the European Union. July 25, 2014